Maitra Anirban, Adsay N Volkan, Argani Pedram, Iacobuzio-Donahue Christine, De Marzo Angelo, Cameron John L, Yeo Charles J, Hruban Ralph H
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Mod Pathol. 2003 Sep;16(9):902-12. doi: 10.1097/01.MP.0000086072.56290.FB.
A multistep model for pancreatic adenocarcinoma has been proposed recently. In this model, well-defined, noninvasive ductal lesions are recognized as precursors of invasive cancer and have been classified under the nomenclature of pancreatic intraepithelial neoplasia, or PanIN. Increasing evidence suggests that PanINs represent true neoplasms of the pancreatic ductal epithelium, accumulating histologic and genetic abnormalities in their progression toward invasive cancer. We have constructed a tissue microarray containing 55 PanIN lesions of all histologic grades in order to perform a multicomponent analysis of the pancreatic adenocarcinoma progression model. The protein products of 14 genes encompassing a variety of functional classes, such as tumor suppressor genes (p53, Smad4/Dpc4), oncogenes (beta-catenin), cell cycle antigens (p16, cyclin D1), proliferation antigens (Ki-67, topoisomerase II alpha), and epithelial apomucins (MUC1, MUC2, MUC5), as well as "novel" genes described as differentially up-regulated in invasive pancreas cancer by global microarray expression analysis (mesothelin, prostate stem cell antigen, fascin, and 14-3-3varsigma), were analyzed by immunohistochemistry on the PanIN tissue microarray. Comparison of the results from the current study with previously published data performed on routine histologic sections of PanINs demonstrates that tissue microarrays are a valid platform for molecular analysis not only of invasive cancers but of precursor lesions as well. In addition, this study demonstrates that molecular abnormalities in PanINs are not random but can usually be stratified into "early" changes (e.g., expression of MUC5 and prostate stem antigen, or loss of p16), "intermediate" changes (e.g., expression of cyclin D1), and "late" changes (e.g., expression of p53, proliferation antigens, MUC1, mesothelin, and 14-3-3varsigma, or loss of Smad4/Dpc4). Understanding the molecular pathogenesis of precursor lesions of invasive pancreatic adenocarcinomas using a high-throughput tissue microarray-based approach is a valuable adjunct to designing rational strategies for early detection of this lethal neoplasm.
最近有人提出了一种胰腺癌的多步骤模型。在这个模型中,明确的非侵袭性导管病变被认为是侵袭性癌症的前体,并已根据胰腺上皮内瘤变(PanIN)的命名法进行分类。越来越多的证据表明,PanIN代表胰腺导管上皮的真正肿瘤,在其向侵袭性癌症进展过程中积累组织学和基因异常。我们构建了一个包含所有组织学分级的55个PanIN病变的组织微阵列,以便对胰腺癌进展模型进行多组分分析。通过免疫组织化学在PanIN组织微阵列上分析了14个基因的蛋白质产物,这些基因涵盖了各种功能类别,如肿瘤抑制基因(p53、Smad4/Dpc4)、癌基因(β-连环蛋白)、细胞周期抗原(p16、细胞周期蛋白D1)、增殖抗原(Ki-67、拓扑异构酶IIα)、上皮粘蛋白(MUC1、MUC2、MUC5),以及通过全局微阵列表达分析被描述为在侵袭性胰腺癌中差异上调的“新”基因(间皮素、前列腺干细胞抗原、丝状肌动蛋白和14-3-3varsigma)。将本研究结果与之前在PanIN常规组织切片上发表的数据进行比较表明,组织微阵列不仅是侵袭性癌症分子分析的有效平台,也是前体病变分子分析的有效平台。此外,本研究表明,PanIN中的分子异常并非随机出现,通常可分为“早期”变化(如MUC5和前列腺干细胞抗原的表达,或p16的缺失)、“中期”变化(如细胞周期蛋白D1的表达)和“晚期”变化(如p53、增殖抗原、MUC1、间皮素和14-3-3varsigma的表达,或Smad4/Dpc4的缺失)。使用基于高通量组织微阵列的方法了解侵袭性胰腺腺癌前体病变的分子发病机制,对于设计这种致命肿瘤的早期检测合理策略是一项有价值的辅助手段。